Who
Dirk Thye
CEO and CMO
Company insider
Files Form 4 as: CEO and CMO, Quince Therapeutics; Chief Medical Officer, Cidara Therapeutics.
In numbers
- Trades disclosed
- 22
- Buys
- 4
- Sells
- 0
- Bought
- $317K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 16 Mar 2016
- Last trade
- 23 Jan 2026
- Last filed
- 23 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Jan 2026filed 23 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 23 Jan 2026filed 23 Jan 2026 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,000,000 at $0.00 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Quince TherapeuticsBiotechnology | SEC FORM 4 Code G | —739,885 at $0.00 | filing |
| 10 Dec 2025filed 12 Dec 2025 | Quince TherapeuticsBiotechnology | SEC FORM 4 Code G | —739,885 at $0.00 | filing |
| 18 Jun 2025filed 23 Jun 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $20K150,944 at $0.13 | filing |
| 18 Jun 2025filed 23 Jun 2025 | Quince TherapeuticsBiotechnology | SEC FORM 4 Code A | $181K150,944 at $1.20 | filing |
| 28 Jan 2025filed 11 Feb 2025 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,200,000 at $0.00 | filing |
| 30 Aug 2024filed 3 Sep 2024 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $54K77,000 at $0.70 | filing |
| 29 Aug 2024filed 3 Sep 2024 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $53K77,500 at $0.69 | filing |
| 1 Feb 2024filed 2 Feb 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,500,000 at $0.00 | filing |
| 16 Jan 2024filed 17 Jan 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —90,531 at $0.00 | filing |
| 16 Jan 2024filed 17 Jan 2024 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —149,999 at $0.00 | filing |
| 16 Jan 2024filed 17 Jan 2024 | Quince TherapeuticsBiotechnology | SEC FORM 4 Code M | $50K90,531 at $0.55 | filing |
| 16 Jan 2024filed 17 Jan 2024 | Quince TherapeuticsBiotechnology | SEC FORM 4 Code M | $141K149,999 at $0.94 | filing |
| 10 Aug 2023filed 11 Aug 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $111K88,000 at $1.26 | filing |
| 8 Aug 2023filed 9 Aug 2023 | Quince TherapeuticsBiotechnology | SEC FORM 4 Bought | $99K80,000 at $1.24 | filing |
| 1 Feb 2023filed 2 Feb 2023 | Quince Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 23 May 2022filed 23 May 2022 | IRLA IRulya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,979,650 at $0.00 | filing |
| 19 May 2022filed 27 May 2022 | IRLA IRulya TherapeuticsBiotechnology | SEC FORM 4 Code A | —216,322 at $0.00 | filing |
| 19 May 2022filed 23 May 2022 | IRLA IRulya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —206,391 | filing |
News
No headline names them, or the companies they trade most, lately.